The research team, led by Timo Purmonen of Oriola together with colleagues from Takeda Oy, Kuopio University Hospital and Terveystalo, conducted a nationwide retrospective matched cohort study using Finnish administrative register data. They identified all individuals of any age who received a new ADHD diagnosis or related record during 2015 to 2020, and matched each of them with up to four controls of the same age, sex and region who had no recorded ADHD. Every participant was then followed from their index date until death, emigration, or the end of 2021, yielding an average follow-up of 3.5 years. The final study population comprised 64,752 individuals with newly identified ADHD and 256,270 matched controls, a dataset of extraordinary statistical power.

What makes this study technically distinctive is its foundation in linked national registers rather than self-reported surveys or clinical samples. Finnish law permits the secondary use of pseudonymised administrative data under the Act on the Secondary Use of Health and Social Data, and the researchers obtained statutory data permits from the Finnish Social and Health Data Permit Authority Findata, Statistics Finland, the Finnish National Agency for Education and the Legal Register Centre. This allowed them to track academic performance, educational attainment, employment status, social benefit payments, marital status, criminal convictions, healthcare resource utilization and both direct and indirect costs across the entire population, without the selection bias and attrition that plague conventional cohort studies. Because the design was observational, the authors emphasize that it was not built to establish whether diagnosis or treatment causes the observed differences.

The educational findings are sobering. Individuals with newly identified ADHD showed consistently poorer academic performance and lower educational attainment than their matched peers. This matters because educational attainment is one of the strongest predictors of lifetime earnings, health and social stability, and a deficit established early can compound across decades. The register approach captured these outcomes across all ages, meaning the study could document not just how children with ADHD fare in school, but how adults who were identified later in life had already diverged from the population baseline in their completed qualifications.

Employment outcomes revealed some of the widest gaps in the entire study. Long-term unemployment was substantially more common among individuals with ADHD than among controls: 15.3 percent of females with ADHD versus 8.2 percent of female controls, and 20.5 percent of males with ADHD versus 10.7 percent of male controls. In other words, men with newly identified ADHD were nearly twice as likely to be out of work long term as their peers, and women were similarly disadvantaged. These figures translate directly into lost productivity and increased reliance on social transfers, which the cost analysis quantified in euros.

Perhaps the most striking single statistic concerns the criminal justice system. Imprisonment was recorded far more frequently among individuals with ADHD, particularly males, at 5.1 percent compared with 1.1 percent in matched controls, a more than fourfold difference. While the study was not designed to explain this association, it is consistent with a large body of international research linking impulsivity, substance use and socioeconomic disadvantage in ADHD to elevated rates of criminal convictions. The finding underscores that the burden of the disorder is borne not only by individuals and health systems but also by the justice sector and, ultimately, by society at large.

Healthcare utilization told a similarly consistent story. Across every age group, individuals with ADHD used more healthcare resources than controls, with the largest differences observed in psychiatric secondary care. Among adults, annual direct healthcare costs reached €4,290 for females with ADHD compared with €1,795 for female controls, and €3,641 for males with ADHD compared with just €1,082 for male controls. That means adult men with ADHD generated more than three times the direct healthcare costs of their matched peers, and adult women roughly two and a half times. The elevated psychiatric care burden suggests that comorbid mental health conditions, which are common in ADHD, drive much of this excess utilization.

The economic analysis extended beyond healthcare to income and welfare. Annual earned income was €7,031 lower among females with ADHD and €10,745 lower among males with ADHD than among matched controls. At the same time, annual social transfer payments were €2,806 higher for females and €2,695 higher for males with the disorder. Taken together, these figures describe a double burden: individuals with ADHD earn substantially less while drawing more in public support, and the health system spends far more on their care. Multiplied across tens of thousands of affected individuals, the aggregate societal cost is enormous, even before accounting for the intangible costs of reduced wellbeing and opportunity.

The study’s scale and rigor give its conclusions unusual weight, but the authors are careful about interpretation. Because the cohort consisted of people with newly identified ADHD during a period when diagnostic rates in Finland were rising sharply, the sample likely includes many adults diagnosed late in life, a group whose socioeconomic difficulties may have contributed to their eventually coming to clinical attention. The observational design cannot separate the effects of the disorder itself from those of comorbidities, treatment access or social circumstances. The study was also funded by Takeda Oy, a pharmaceutical manufacturer, though the sponsor reports having had no role in study design, data analysis or interpretation, and the authors declare no competing interests. These caveats do not diminish the descriptive power of the data; they simply frame what the numbers can and cannot tell us.

What the numbers do tell us is unambiguous: the burden of ADHD extends far beyond healthcare into education, labor markets, welfare systems and the criminal justice system. For policymakers, the study provides a national-scale evidence base for investing in earlier identification, better access to treatment and supported transitions from school to work. For clinicians, it is a reminder that an ADHD diagnosis carries implications that reach into every domain of a patient’s life. And for the hundreds of thousands of people living with the disorder and their families, it offers validation that the challenges they face are real, measurable and shared by a substantial fraction of the population. As diagnostic rates continue to climb across the developed world, studies of this kind will be essential for deciding where scarce public resources can do the most good.

Subject of Research: The educational, socioeconomic, healthcare and societal burden of newly identified ADHD in Finland

Article Title: Burden of attention deficit hyperactivity disorder (ADHD) on people and society in Finland – a nationwide register study in 2015–2021

Article References: Purmonen, T., Iso-Mustajärvi, I., Kallio, A., Jukka, J., Puustjärvi, A., & Leppämäki, S. (2026). Burden of attention deficit hyperactivity disorder (ADHD) on people and society in Finland – a nationwide register study in 2015–2021. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08729-z

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08729-z

Keywords: ADHD, Finland, register study, disease burden, healthcare costs, unemployment, education, criminal convictions, social benefits, cohort study, psychiatry, socioeconomic outcomes